New take on the role of angiotensin II in cardiac hypertrophy and fibrosis

Hypertension

Volumn 57, Issue 6, 2011, Pages 1034-1038

  Kurdi, Mazen ^a,b   Booz, George W ^b  

^a LEBANESE UNIVERSITY   (Lebanon)

^b UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

ACE2; adiponectin; aldosterone; angiotensin i converting enzyme; angiotensin II type 1 receptor; cardiac remodeling; left ventricular hypertrophy; renin angiotensin system

Indexed keywords

ALDOSTERONE; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN II; APOPTOSIS SIGNAL REGULATING KINASE 1; C REACTIVE PROTEIN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM; TRANSFORMING GROWTH FACTOR BETA1;

ADRENERGIC SYSTEM; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; HEART MUSCLE FIBROSIS; HEART VENTRICLE HYPERTROPHY; HUMAN; HYPERTENSION; INFLAMMATION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

EID: 85027947959     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.111.172700     Document Type: Article

References (38)

1. Reudelhuber TL, Bernstein KE, Delafontaine P. Is angiotensin II a direct mediator of left ventricular hypertrophy? Time for another look. Hypertension. 2007;49:1196-1201. (Pubitemid 46809352)
2. Xu J, Carretero OA, Liao TD, Peng H, Shesely EG, Xu J, Liu TS, Yang JJ, Reudelhuber TL, Yang XP. Local angiotensin II aggravates cardiac remodeling in hypertension. Am J Physiol Heart Circ Physiol. 2010;299: H1328-H1338.
3. Eißler R, Schmaderer C, Rusai K, Kühne L, Sollinger D, Lahmer T, Witzke O, Lutz J, Heemann U, Baumann M. Hypertension augments cardiac Toll-like receptor 4 expression and activity. Hypertens Res. In press.
4. Danser AH. Cardiac angiotensin II: does it have a function? Am J Physiol Heart Circ Physiol. 2010;299:H1304-H1306.
5. Wei CC, Hase N, Inoue Y, Bradley EW, Yahiro E, Li M, Naqvi N, Powell PC, Shi K, Takahashi Y, Saku K, Urata H, Dell'italia LJ, Husain A. Mast cell chymase limits the cardiac efficacy of Ang I-converting enzyme inhibitor therapy in rodents. J Clin Invest. 2010;120:1229-1239.
6. Griendling KK, Sorescu D, Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res. 2000;86:494-501. (Pubitemid 30165039)
7. Wang M, Zhang J, Walker SJ, Dworakowski R, Lakatta EG, Shah AM. Involvement of NADPH oxidase in age-associated cardiac remodeling. J Mol Cell Cardiol. 2010;48:765-772.
8. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, Ota M, Nagai K, Araki T, Satoh H, Ito S, Hisamichi S, Imai Y. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama Study. Hypertension. 2000;36:901-906.
9. Kudo H, Kai H, Kajimoto H, Koga M, Takayama N, Mori T, Ikeda A, Yasuoka S, Anegawa T, Mifune H, Kato S, Hirooka Y, Imaizumi T. Exaggerated blood pressure variability superimposed on hypertension aggravates cardiac remodeling in rats via angiotensin II system-mediated chronic inflammation. Hypertension. 2009;54:832-838.
10. Mukaddam-Daher S, Menaouar A, Paquette PA, Jankowski M, Gutkowska J, Gillis MA, Shi YF, Calderone A, Tardif JC. Hemodynamic and cardiac effects of chronic eprosartan and moxonidine therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2009;53: 775-781.
11. Levick SP, McLarty JL, Murray DB, Freeman RM, Carver WE, Brower GL. Cardiac mast cells mediate left ventricular fibrosis in the hypertensive rat heart. Hypertension. 2009;53:1041-1047.
12. Levick SP, Murray DB, Janicki JS, Brower GL. Sympathetic nervous system modulation of inflammation and remodeling in the hypertensive heart. Hypertension. 2010;55:270-276.
13. Jin Y, Kuznetsova T, Maillard M, Richart T, Thijs L, Bochud M, Herregods MC, Burnier M, Fagard R, Staessen JA. Independent relations of left ventricular structure with the 24-hour urinary excretion of sodium and aldosterone. Hypertension. 2009;54:489-495.
14. du Cailar G, Fesler P, Ribstein J, Mimran A. Dietary sodium, aldosterone, and left ventricular mass changes during long-term inhibition of the renin-angiotensin system. Hypertension. 2010;56:865-870.
15. Di Zhang A, Nguyen Dinh Cat A, Soukaseum C, Escoubet B, Cherfa A, Messaoudi S, Delcayre C, Samuel JL, Jaisser F. Cross-talk between mineralocorticoid and angiotensin II signaling for cardiac remodeling. Hypertension. 2008;52:1060-1067.
16. Nakamura T, Kataoka K, Fukuda M, Nako H, Tokutomi Y, Dong YF, Ichijo H, Ogawa H, Kim-Mitsuyama S. Critical role of apoptosis signalregulating kinase 1 in aldosterone/salt-induced cardiac inflammation and fibrosis. Hypertension. 2009;54:544-551.
17. Ardanaz N, Yang XP, Cifuentes ME, Haurani MJ, Jackson KW, Liao TD, Carretero OA, Pagano PJ. Lack of glutathione peroxidase 1 accelerates cardiac-specific hypertrophy and dysfunction in angiotensin II hypertension. Hypertension. 2010;55:116-123.
18. Lin L, Gong H, Ge J, Jiang G, Zhou N, Li L, Ye Y, Zhang G, Ge J, Zou Y. High density lipoprotein downregulates angiotensin II type 1 receptor and inhibits angiotensin II-induced cardiac hypertrophy. Biochem Biophys Res Commun. 2011;404:28-33.
19. Jeppesen J, Asferg C. C-reactive protein and cardiovascular disease: differences between humans and mice. Hypertension. 2010;56:e15.
20. Zhang R, Zhang YY, Huang XR, Wu Y, Chung AC, Wu EX, Szalai AJ, Wong BC, Lau CP, Lan HY. C-reactive protein promotes cardiac fibrosis and inflammation in angiotensin II-induced hypertensive cardiac disease. Hypertension. 2010;55:953-960.
21. Huang XR, Chung AC, Yang F, Yue W, Deng C, Lau CP, Tse HF, Lan HY. Smad3 mediates cardiac inflammation and fibrosis in angiotensin II-induced hypertensive cardiac remodeling. Hypertension. 2010;55: 1165-1171.
22. Graf K, Schaefer-Graf UM. Is Smad3 the key to inflammation and fibrosis in hypertensive heart disease? Hypertension. 2010;55:1088-1089.
23. Yagi S, Akaike M, Aihara K, Ishikawa K, Iwase T, Ikeda Y, Soeki T, Yoshida S, Sumitomo-Ueda Y, Matsumoto T, Sata M. Endothelial nitric oxide synthase-independent protective action of statin against angiotensin II-induced atrial remodeling via reduced oxidant injury. Hypertension. 2010;55:918-923.
24. Sumitomo-Ueda Y, Aihara K, Ise T, Yoshida S, Ikeda Y, Uemoto R, Yagi S, Iwase T, Ishikawa K, Hirata Y, Akaike M, Sata M, Kato S, Matsumoto T. Heparin cofactor II protects against angiotensin II-induced cardiac remodeling via attenuation of oxidative stress in mice. Hypertension. 2010;56:430-436.
25. Nabeebaccus A, Zhang M, Shah AM. NADPH oxidases and cardiac remodelling. Heart Fail Rev. 2011;16:5-12.
26. Maejima Y, Kuroda J, Matsushima S, Ago T, Sadoshima J. Regulation of myocardial growth and death by NADPH oxidase. J Mol Cell Cardiol. 2011;50:408-416.
27. Touyz RM, Mercure C, He Y, Javeshghani D, Yao G, Callera GE, Yogi A, Lochard N, Reudelhuber TL. Angiotensin II-dependent chronic hypertension and cardiac hypertrophy are unaffected by gp91phox-containing NADPH oxidase. Hypertension. 2005;45:530-537. (Pubitemid 40411255)
28. Wakui H, Tamura K, Tanaka Y, Matsuda M, Bai Y, Dejima T, Masuda S, Shigenaga A, Maeda A, Mogi M, Ichihara N, Kobayashi Y, Hirawa N, Ishigami T, Toya Y, Yabana M, Horiuchi M, Minamisawa S, Umemura S. Cardiac-specific activation of angiotensin II type 1 receptor-associated protein completely suppresses cardiac hypertrophy in chronic angiotensin II-infused mice. Hypertension. 2010;55:1157-1164.
29. Cai J, Yi FF, Yang L, Shen DF, Yang Q, Li A, Ghosh AK, Bian ZY, Yan L, Tang QZ, Li H, Yang XC. Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. Hypertension. 2009;53:539-548.
30. Díez J, González A, Ravassa S. Is the deficiency of the long isoform of cellular FLICE-inhibitory protein involved in myocardial remodeling? Hypertension. 2010;56:1045-1046.
31. Li H, Tang QZ, Liu C, Moon M, Chen M, Yan L, Bian ZY, Zhang Y, Wang AB, Nghiem MP, Liu PP. Cellular FLICE-inhibitory protein protects against cardiac remodeling induced by angiotensin II in mice. Hypertension. 2010;56:1109-1117.
32. Gomes ER, Lara AA, Almeida PW, Guimarães D, Resende RR, Campagnole-Santos MJ, Bader M, Santos RA, Guatimosim S. Angiotensin-( 1-7) prevents cardiomyocyte pathological remodeling through anitric oxide/guanosine 3′,5′-cyclic monophosphate-dependent pathway. Hypertension. 2010;55:153-160.
33. Booz GW. Putting the brakes on cardiac hypertrophy: exploiting the NO-cGMP counter-regulatory system. Hypertension. 2005;45: 341-346. (Pubitemid 40315798)
34. Santiago NM, Guimarães PS, Sirvente RA, Oliveira LA, Irigoyen MC, Santos RA, Campagnole-Santos MJ. Lifetime overproduction of circulating Angiotensin-(1-7) attenuates deoxycorticosterone acetate-salt hypertension-induced cardiac dysfunction and remodeling. Hypertension. 2010;55:889-896.
35. Li P, Shibata R, Unno K, Shimano M, Furukawa M, Ohashi T, Cheng X, Nagata K, Ouchi N, Murohara T. Evidence for the importance of adiponectin in the cardioprotective effects of pioglitazone. Hypertension. 2010;55:69-75.
36. Li J, Zhang C, Xing Y, Janicki JS, Yamamoto M, Wang XL, Tang DQ, Cui T. Up-regulation of p27kip1 contributes to Nrf2-mediated protection against angiotensin II-induced cardiac hypertrophy. Cardiovasc Res. 2011;90:315-324.
37. Booz GW. Novel drugs targeting hypertension revisited. J Cardiovasc Pharmacol. 2010;56:213-214.
38. Yasuda N, Akazawa H, Qin Y, Zou Y, Komuro I. A novel mechanism of mechanical stress-induced angiotensin II type 1-receptor activation without the involvement of angiotensin II. Naunyn Schmiedebergs Arch Pharmacol. 2008;377:393-399.